AR047747A1 - Moduladores de furosemida de hm74 - Google Patents
Moduladores de furosemida de hm74Info
- Publication number
- AR047747A1 AR047747A1 ARP050100596A ARP050100596A AR047747A1 AR 047747 A1 AR047747 A1 AR 047747A1 AR P050100596 A ARP050100596 A AR P050100596A AR P050100596 A ARP050100596 A AR P050100596A AR 047747 A1 AR047747 A1 AR 047747A1
- Authority
- AR
- Argentina
- Prior art keywords
- contain
- substituted
- combinations
- heteroatom
- branched
- Prior art date
Links
- 101001035752 Homo sapiens Hydroxycarboxylic acid receptor 3 Proteins 0.000 title abstract 2
- 102100039356 Hydroxycarboxylic acid receptor 3 Human genes 0.000 title abstract 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 title 1
- 229960003883 furosemide Drugs 0.000 title 1
- 125000005842 heteroatom Chemical group 0.000 abstract 10
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 230000007781 signaling event Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54601104P | 2004-02-20 | 2004-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR047747A1 true AR047747A1 (es) | 2006-02-15 |
Family
ID=34910746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050100596A AR047747A1 (es) | 2004-02-20 | 2005-02-18 | Moduladores de furosemida de hm74 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7232811B2 (enExample) |
| EP (1) | EP1718292A1 (enExample) |
| JP (1) | JP2007523166A (enExample) |
| KR (1) | KR20060127141A (enExample) |
| CN (1) | CN1921845A (enExample) |
| AR (1) | AR047747A1 (enExample) |
| AU (1) | AU2005216879B2 (enExample) |
| BR (1) | BRPI0506792A (enExample) |
| CA (1) | CA2557444A1 (enExample) |
| CR (1) | CR8528A (enExample) |
| EC (1) | ECSP066777A (enExample) |
| IL (1) | IL177086A (enExample) |
| MA (1) | MA28373A1 (enExample) |
| ME (1) | MEP21108A (enExample) |
| MX (1) | MXPA06008612A (enExample) |
| NO (1) | NO20064237L (enExample) |
| NZ (1) | NZ548830A (enExample) |
| RS (1) | RS20060473A (enExample) |
| RU (1) | RU2006133540A (enExample) |
| SG (1) | SG164305A1 (enExample) |
| TN (1) | TNSN06234A1 (enExample) |
| TW (1) | TW200538109A (enExample) |
| WO (1) | WO2005082350A1 (enExample) |
| ZA (1) | ZA200606679B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8008283B2 (en) | 1998-12-23 | 2011-08-30 | Neurotherapeutics Pharma, Inc. | Methods and compositions for the treatment of neuropsychiatric disorders |
| US7094572B2 (en) | 2003-03-14 | 2006-08-22 | Bristol-Myers Squibb | Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74 |
| WO2006060461A1 (en) | 2004-12-03 | 2006-06-08 | Schering Corporation | Substituted piperazines as cb1 antagonists |
| EP1968603A4 (en) * | 2006-01-03 | 2013-01-16 | Algebra Inc | THERAPEUTIC AMINARYLSULFONAMIDE CONJUGATE COMPOUNDS |
| BRPI0706623A2 (pt) * | 2006-01-18 | 2011-04-12 | Schering Corp | moduladores de receptor canabinóide |
| US7906555B2 (en) | 2006-10-26 | 2011-03-15 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance |
| US20100197564A1 (en) * | 2007-04-19 | 2010-08-05 | Schering Corporation | Diaryl morpholines as cb1 modulators |
| US20100286160A1 (en) * | 2007-06-28 | 2010-11-11 | Intervet Inc. | Substituted piperazines as cb1 antagonists |
| EP2548874A3 (en) * | 2007-06-28 | 2013-05-15 | Intervet International B.V. | Substituted piperazines as CB1 antagonists |
| LT6401B (lt) * | 2015-07-28 | 2017-06-12 | Vilniaus Universitetas | Karboanhidrazės selektyvūs inhibitoriai |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3875150A (en) | 1969-04-29 | 1975-04-01 | Leo Pharm Prod Ltd | New sulfamyl-anthranilic acids |
| GB1260155A (en) * | 1969-04-29 | 1972-01-12 | Leo Pharm Prod Ltd | Sulphonamido anthranilic acid derivatives |
| AT324318B (de) * | 1971-02-15 | 1975-08-25 | Dumex Ltd As | Verfahren zur herstellung von furanderivaten |
| DE2247828A1 (de) * | 1972-09-29 | 1974-04-04 | Hoechst Ag | Sulfamoyl-anthranilsaeuren und verfahren zu ihrer herstellung |
| DE2406972C3 (de) * | 1974-02-14 | 1979-07-19 | Hoechst Ag, 6000 Frankfurt | Verfahren zur Herstellung von 5-Sulfamoylanthranilsäuren |
| DE2718871C3 (de) * | 1977-04-28 | 1980-07-17 | Hoechst Ag, 6000 Frankfurt | N-(2-Furylmethyl)-5-sulfamoylorthanilsäuren und deren physiologisch verträgliche Salze und Verfahren zu ihrer Herstellung und ihre Verwendung bei der Bekämpfung von Oedemkrankheiten und Bluthochdruck |
| US4406896A (en) * | 1979-12-20 | 1983-09-27 | Merck & Co., Inc. | Adjuvants for rectal delivery of drug substances |
| DE3006686A1 (de) * | 1980-02-22 | 1981-08-27 | Hoechst Ag, 6000 Frankfurt | 5-sulfamoyl-orthanilsaeuren, verfahren zu ihrer herstellung und ihre verwendung als heilmittel |
| DE3041812A1 (de) * | 1980-11-06 | 1982-06-16 | Hoechst Ag, 6000 Frankfurt | Basisch substituierte 5-phenyltetrazole, verfahren zu ihrer herstellung und ihre verwendung als heilmittel |
| DE3101960A1 (de) * | 1981-01-22 | 1982-09-02 | Hoechst Ag, 6000 Frankfurt | "basisch substituierte anthranilsaeuren, verfahren zu ihrer herstellung und ihre verwendung" |
| US5256687A (en) * | 1985-09-09 | 1993-10-26 | Hoechst Aktiengesellschaft | Pharmaceutical composition for the treatment of high blood pressure |
| JPH0720862B2 (ja) * | 1989-01-27 | 1995-03-08 | ヘキスト・アクチエンゲゼルシヤフト | 吸入用喘息治療剤 |
| JP2002508660A (ja) * | 1997-06-12 | 2002-03-19 | スミスクライン ビーチャム コーポレーション | Ｈｍ７４ａ受容体 |
| GB0021484D0 (en) * | 2000-09-01 | 2000-10-18 | Boehringer Ingelheim Pharma | Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases |
| DE10060809A1 (de) * | 2000-12-07 | 2002-06-20 | Aventis Pharma Gmbh | Substituierte Anthranilsäuren, ihre Verwendung als Medikament oder Diagnostikum, sowie sie enthaltendes Medikament, sowie ein pharmazeutisches Kombinationspräparat mit einem Natrium/Wasserstoff-Austausch (NHE)-Blocker |
| US20030109673A1 (en) * | 2002-10-04 | 2003-06-12 | Xiao Yonghong | Regulation of human hm74-like g protein coupled receptor |
-
2005
- 2005-02-10 KR KR1020067016657A patent/KR20060127141A/ko not_active Withdrawn
- 2005-02-10 JP JP2006554129A patent/JP2007523166A/ja active Pending
- 2005-02-10 CN CNA2005800054570A patent/CN1921845A/zh active Pending
- 2005-02-10 MX MXPA06008612A patent/MXPA06008612A/es active IP Right Grant
- 2005-02-10 CA CA002557444A patent/CA2557444A1/en not_active Abandoned
- 2005-02-10 RU RU2006133540/04A patent/RU2006133540A/ru not_active Application Discontinuation
- 2005-02-10 WO PCT/US2005/004108 patent/WO2005082350A1/en not_active Ceased
- 2005-02-10 NZ NZ548830A patent/NZ548830A/en unknown
- 2005-02-10 EP EP05713210A patent/EP1718292A1/en not_active Withdrawn
- 2005-02-10 AU AU2005216879A patent/AU2005216879B2/en not_active Ceased
- 2005-02-10 RS RSP-2006/0473A patent/RS20060473A/sr unknown
- 2005-02-10 SG SG200901539-7A patent/SG164305A1/en unknown
- 2005-02-10 BR BRPI0506792-8A patent/BRPI0506792A/pt not_active IP Right Cessation
- 2005-02-10 ME MEP-211/08A patent/MEP21108A/xx unknown
- 2005-02-14 US US11/057,587 patent/US7232811B2/en not_active Expired - Fee Related
- 2005-02-18 TW TW094104731A patent/TW200538109A/zh unknown
- 2005-02-18 AR ARP050100596A patent/AR047747A1/es not_active Application Discontinuation
-
2006
- 2006-07-24 CR CR8528A patent/CR8528A/es not_active Application Discontinuation
- 2006-07-25 IL IL177086A patent/IL177086A/en not_active IP Right Cessation
- 2006-07-28 TN TNP2006000234A patent/TNSN06234A1/en unknown
- 2006-08-11 ZA ZA200606679A patent/ZA200606679B/xx unknown
- 2006-08-18 EC EC2006006777A patent/ECSP066777A/es unknown
- 2006-08-29 MA MA29295A patent/MA28373A1/fr unknown
- 2006-09-19 NO NO20064237A patent/NO20064237L/no not_active Application Discontinuation
-
2007
- 2007-05-07 US US11/745,131 patent/US7556931B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20070213391A1 (en) | 2007-09-13 |
| US7556931B2 (en) | 2009-07-07 |
| ZA200606679B (en) | 2008-01-30 |
| WO2005082350A8 (en) | 2005-12-08 |
| NO20064237L (no) | 2006-09-19 |
| SG164305A1 (en) | 2010-09-29 |
| NZ548830A (en) | 2010-03-26 |
| MEP21108A (en) | 2010-06-10 |
| AU2005216879A1 (en) | 2005-09-09 |
| MXPA06008612A (es) | 2007-01-25 |
| CA2557444A1 (en) | 2005-09-09 |
| IL177086A0 (en) | 2006-12-10 |
| CR8528A (es) | 2007-06-08 |
| EP1718292A1 (en) | 2006-11-08 |
| IL177086A (en) | 2010-06-16 |
| AU2005216879B2 (en) | 2009-12-10 |
| ECSP066777A (es) | 2006-11-16 |
| RU2006133540A (ru) | 2008-03-27 |
| KR20060127141A (ko) | 2006-12-11 |
| US20050187280A1 (en) | 2005-08-25 |
| WO2005082350A1 (en) | 2005-09-09 |
| RS20060473A (sr) | 2008-08-07 |
| TW200538109A (en) | 2005-12-01 |
| US7232811B2 (en) | 2007-06-19 |
| CN1921845A (zh) | 2007-02-28 |
| BRPI0506792A (pt) | 2007-05-22 |
| JP2007523166A (ja) | 2007-08-16 |
| MA28373A1 (fr) | 2006-12-01 |
| TNSN06234A1 (en) | 2007-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0414541B8 (pt) | compostos heterocíclicos fundidos tendo atividade de modulação de receptor de serotonina, método de preparação de compostos intermediários | |
| AR107966A2 (es) | Derivados de pirimidina y piridina inhibidores de la proteína quinasa | |
| CO5550436A2 (es) | Derivados de benzamida | |
| DE59608740D1 (de) | Cyclische und heterocyclische n-substituierte alpha-iminohydroxam- und carbonsäuren | |
| AR037736A1 (es) | Derivados de pirimidina como moduladores o inhibidores de la actividad del factor de crecimiento insulinico tipo 1 (igf-1r) | |
| ECSP077273A (es) | Moduladores de quinasa de anillo heterocíclico fusionado | |
| DE3879292D1 (de) | Substituierte aromatische sulfonamide als mittel gegen glaukom. | |
| BR0114657A (pt) | Compostos de benzamida e seu uso | |
| AR016817A1 (es) | Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento | |
| AR060405A1 (es) | Compuestos organicos y sus usos en tratamientos de infeccion por el virus de hepatitis c | |
| EP1267616A4 (en) | METHOD FOR MODULATING HAIR GROWTH | |
| ES2037752T3 (es) | Utilizacion de un derivado de benzoxazol y su procedimiento de preparacion. | |
| PE20040581A1 (es) | Inhibidores heterociclicos de cinasas | |
| UY26130A1 (es) | Compuestos para tratar la obesidad | |
| PE20141280A1 (es) | Inhibidores de aplicacion viral | |
| AR065784A1 (es) | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. | |
| CY1109954T1 (el) | Διαδερμικο θεραπευτικο συστημα (tts) με τη δραστικη ουσια φεντανυλη | |
| AR018204A1 (es) | METODO PARA LA PREPARACIOON DE CITALOPRAM , INTERMEDIARIO PARA LA PREPARACION DE CITALOPRAM Y EL USO DEL INTERMEDIARIO PARA LA PREPARACIoN DE CITALOPRAM | |
| ES2213007T3 (es) | Derivados de 4,5-diaril-3(2h)-furanona como inhibidores de la ciclooxigenasa-2. | |
| AR042273A1 (es) | Derivados de pirazol, procedimiento para prepararlos y las composiciones farmaceuticas que los contienen | |
| UY28186A1 (es) | N-arilheterociclos sustituidos, procedimientos para su preparación, y su empleo como medicamentos. | |
| CO6321264A2 (es) | Derivados de 1-heterociclilo-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona y su uso como moduladores de la pde9a | |
| DE60118544D1 (de) | Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren | |
| AR121275A1 (es) | Compuesto de sulfonamida o sulfinamida que tiene acción inhibidora de la proteína brd4 y su uso como medicamento | |
| ECSP055918A (es) | Procedimiento para modificar la formación de cristal de fármaco |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |